Aaisha Memon MBBS, PG Dip,1, Bilal Fazal Shaikh MBBS, MS,MBBS, MS 2,Saba Khan MBBS, PG Dip3Raheela Bilal Shaikh, MBBS, DGO 4, Syed Zafar Abbas BDS, MCPS
Abstract:
Abstract
Background: Mesotherapy involves micro-injections of pharmaceutical compounds into the dermis to treat various skin disorders, including melasma. This study aims to compare the efficacy of tranexamic acid (TXA) administered via mesotherapy versus oral TXA in treating melasma.
Objective: To assess and compare the effectiveness of tranexamic acid mesotherapy versus oral tranexamic acid in the management of melasma.
Methodology: This 12-week interventional randomized controlled trial was conducted in a multi-center, Royal Facial Aesthetic Academy’s affiliated private aesthetic setups in different cities, involving 20 female patients with symmetrical facial melasma aged up to 40. Enrolled patients, with an average MASI score of 30 (range 0-48), were randomly divided into two groups: Group A (N = 10) received oral TXA 250 mg twice daily, and Group B (N = 10) underwent trans epidermal administration of TXA (10 mg/mL) via micro needling every two weeks for 12 weeks.
Results: Twenty participants with a mean age of 30 years (range 20–40) were included. Sixty percent exhibited a centrofacial pattern, while 40% had a malar pattern. Group B demonstrated favorable outcomes, suggesting that tranexamic acid administered intradermally with microneedling is a superior option for melasma treatment.
Conclusion: Intradermal tranexamic acid delivery through microneedling emerges as a cost-effective and novel treatment approach for melasma. This method not only enhances patient compliance but also alleviates stress, improves quality of life, and addresses psychological and social concerns related to melasma.
Full Text http://medicalchannel.pk/wp-content/uploads/2024/08/Vol23Issue2.pdf